Génétique Moléculaire, UMR
8541 CNRS, Ecole Normale Supérieure, 75230 Paris Cedex 05, France,1 and Section of Molecular
and Cellular Biology, University of California, Davis, California
956162
The phosphorylation of the RNA polymerase II (RNAP II)
carboxy-terminal domain (CTD) plays a key role in mRNA metabolism. The relative ratio of hyperphosphorylated RNAP II to hypophosphorylated RNAP II is determined by a dynamic equilibrium between CTD kinases and
CTD phosphatase(s). The CTD is heavily phosphorylated in meiotic Xenopus laevis oocytes. In this report we show that the
CTD undergoes fast and massive dephosphorylation upon fertilization. A
cDNA was cloned and shown to code for a full-length xFCP1, the
Xenopus orthologue of the FCP1 CTD phosphatases in
humans and Saccharomyces cerevisiae. Two critical
residues in the catalytic site were identified. CTD phosphatase
activity was observed in extracts prepared from Xenopus
eggs and cells and was shown to be entirely attributable to xFCP1. The
CTD dephosphorylation triggered by fertilization was reproduced upon
calcium activation of cytostatic factor-arrested egg extracts. Using
immunodepleted extracts, we showed that this dephosphorylation is due
to xFCP1. Although transcription does not occur at this stage,
phosphorylation appears as a highly dynamic process involving the
antagonist action of Xp42 mitogen-activated protein kinase and FCP1
phosphatase. This is the first report that free RNAP II is a
substrate for FCP1 in vivo, independent from a transcription cycle.
 |
INTRODUCTION |
In many metazoans, early development
is characterized by major changes in the global transcriptional
activity of the zygote (13). After fertilization,
development proceeds for a while in the absence of transcription
and is dependent on the translation of maternal mRNAs stored
during ovogenesis. Transcription resumes at a stage which is species
specific and corresponds to the two-cell stage in mice. In
Xenopus laevis, transcription resumes at the 12th cleavage
division at a major developmental transition known as the midblastula
transition. Important changes in RNA polymerase II (RNAP II)
phosphorylation have been described to occur in worm (27),
fly (20), mammalian (3), and amphibian
(25) embryos during this period.
RNAP II phosphorylation is a key event in the transcription cycle
(11, 12). The largest subunit of RNAP II (Rpb1) can be
extensively phosphorylated on its carboxy-terminal domain (CTD), which
is comprised of up to 52 repeats of the consensus heptapeptide Tyr-Ser-Pro-Thr-Ser-Pro-Ser. Thus, in somatic cells, two forms of RNAP
II coexist in a dynamic equilibrium (15). The
hypophosphorylated IIA form assembles into preinitiation complexes,
whereas the hyperphosphorylated IIO form catalyzes transcript
elongation and facilitates the recruitment of the pre-mRNA
processing machinery. CTD dephosphorylation is required to recycle the
polymerase at the end of each round of transcription.
Several CTD kinases have been identified (for reviews, see references
5, 21, and 28): the CDK8 subunit of the
mediator complex in the RNAP II holoenzyme, the CDK7 subunit of the
general transcription factor TFIIH which assembles in the preinitiation complex, the CDK9 subunit of P-TEFb (positive transcription elongation factor b) (26), and the extracellular signal-regulated
kinase-type mitogen-activated protein kinases (MAPKs)
(6). In contrast, only one CTD phosphatase has been
characterized to date (1, 8, 9). Its activity is
stimulated by the transcription factor TFIIF and repressed by TFIIB.
Its only known substrate is the phosphorylated CTD within the RNAP II
core enzyme. The corresponding FCP1 gene (for TFIIF-stimulated CTD
phosphatase 1) is essential in Saccharomyces cerevisiae
(18), and in vitro experiments have established that the
phosphatase activity is necessary to recycle the RNAP II at the end of
a transcription cycle (10).
Here we report the characterization of a CTD phosphatase activity from
Xenopus cells and egg extracts. This activity was
attributable to the frog orthologue of FCP1 and accounts for the RNAP
II dephosphorylation that occurs shortly after fertilization.
Furthermore, the finding that the dephosphorylation of RNAP IIO occurs
prior to the onset of transcription indicates that free RNAP II
is a natural substrate for FCP1.
 |
MATERIALS AND METHODS |
Cells.
A6 cells were propagated in Leibovitz medium
supplemented with fetal calf serum (10%). Subconfluent cells, 24 h after plating, were lysed in PB buffer (50 mM Tris-HCl [pH 7.9], 10 mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 10% glycerol,
0.5 mM dithiothreitol) supplemented with 0.5% Nonidet P-40; the lysate
was centrifuged at 10,000 × g.
Transient transfections were performed in semiconfluent
50-mm-diameter dishes using the classical calcium phosphate
procedure. Plasmid pSP64 was used as a carrier to bring the total
amount of DNA to 10 µg per dish.
Eggs and embryo extracts.
Interphasic egg extract
preparation was adapted from the method of Murray (24).
Eggs were laid in high-salt Barth's medium (15 mM Tris-HCl [pH
7.4], 110 mM NaCl, 2 mM KCl, 1 mM MgSO4, 0.5 mM
Na2HPO4, 2 mM
NaHCO3), dejellied in high-salt Barth's medium supplemented with 2% cysteine (pH 7.8), and activated by 0.25 µg of
calcium ionophore A23187/ml for 5 min. Activated eggs were rinsed in EB
buffer (50 mM HEPES-KOH [pH 7.5], 50 mM KCl, 5 mM
MgCl2, 2 mM dithiothreitol), packed by
centrifugation at 100 × g, and crushed by
centrifugation at 15,000 × g.
Meiotic cytostatic factor (CSF)-arrested egg extracts were prepared
according to the method of Swedlow (29). Activation was
performed by the addition of CaCl2 (1 mM) and
incubation of the extracts at 22°C.
Alternatively, freshly laid eggs were fertilized using dilacerated
testes. Embryos were allowed to develop at 22°C in development medium
(1.5 mM Tris-HCl [pH 7.4], 8.8 mM NaCl, 0.2 mM KCl, 0.1 mM
MgCl2, 100 U of penicillin G/ml, 100 µg of
streptomycin/ml). Unfertilized eggs and embryos were dejellied in
development medium supplemented with 2% cysteine (pH 7.8). Batches of
10 eggs or embryos were crushed in 500 µl of Laemmli buffer, and the
resulting lysate was centrifuged at 15,000 × g for 15 min before being loaded onto sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels for Western blot analysis.
Immunodepletions.
Twenty microliters of protein A-Sepharose
beads (Amersham Pharmacia Biotech) equilibrated in PB buffer was
incubated overnight at 4°C with 20 µl of anti-FCP1 serum or mock
serum. The beads were washed with PB buffer and incubated with 40 µl
of A6 cell extract or 10 µl of egg extract. After 30 min of shaking
at 4°C, the supernatants were recovered.
CTD phosphatase assay.
Purified calf thymus RNAP IIA was
labeled with casein kinase II (Boehringer-Mannheim) in the presence of
[
-32P]ATP. The labeled RNAP IIA was
converted to RNAP IIO by incubation with CTDK1 and 2 mM cold ATP
(8). 32P-labeled RNAP IIO (1,000 to
5,000 cpm, 50 fmol) was incubated with extracts at 30°C in PB buffer
(20-µl final volume). When indicated, the reaction mixture contained
10 nM okadaic acid (Sigma) or 5 nM microcystin-LR (Sigma). Reactions
were stopped by the addition of 20 µl of 2× Laemmli buffer. Samples
were analyzed by SDS-PAGE and autoradiography.
CTD phosphate turnover assay.
Purified calf thymus RNAP IIA
was uniformly labeled on the CTD repeats with CTDK1 in the presence of
[
-32P]ATP. The labeled RNAP II was fully
phosphorylated into RNAP IIO by the subsequent addition of 2 mM cold
ATP. 32P-labeled RNAP IIO was incubated with
extracts at 22°C.
Cloning of Xenopus FCP1 and site-directed
mutagenesis.
Total RNAs were extracted from A6 cells using the
RNeasy kit (Qiagen). The primers ATA TGG ATC CAT GCA AAA TCG AGC TCG
AGA and GCG GCC GCT AAT CTT CAA TTT ACC CTA ATA were used to amplify the full-length xFCP1 open reading frame by reverse transcription-PCR (ThermoscriptRT; Gibco BRL). The 2,943-bp fragment was cloned in the
pcDNA-V5His-TOPO vector (Invitrogen) and sequenced. A
BamHI/NotI restriction fragment was subcloned in
the pGEX4T2 vector (Amersham Pharmacia Biotech) to generate
plasmid pGEX4T2-xFCP1-wt.
Site-directed mutagenesis of pGEX4T2-xFCP1-wt was performed by
successive PCRs. Primary PCRs were performed using the following primers: ATG GTT AAC TTA GAT CAG ACT and AGT CTG ATC TAA GTT AAC CAT
for the D181N mutation; ATG GTT GAT TTA AAC CAG ACT and AGT CTG GTT TAA
ATC AAC CAT for the D183N mutation; ATG GTT GAA TTA GAT CAG ACT and AGT
CTG ATC TAA TTC AAC CAT for the D181E mutation; ATG GTT GAT TTA GAA CAG
ACT and AGT CTG TTC TAA ATC AAC CAT for the D183E mutation; and
upstream primers TCC CAC AAA TTG ATA AGT ACT and CAC ATA CTT TTT AAC
TGT GAT C. Secondary PCR products were digested by BamHI and
EcoRI and used to replace the
BamHI/EcoRI fragment from pGEX4T2-xFCP1-wt,
resulting in pGEX4T2-xFCP1-D181N, pGEX4T2-xFCP1-D183N,
pGEX4T2-xFCP1-D181E, and pGEX4T2-xFCP1-D183E. Insertion of point
mutations was checked by sequencing.
For eukaryotic expression plasmids, primers ATC TAT GCT AGC AAT GCA AAA
TCG AGC TCG and CCG TCG CAT CGA TTC ATA TGA AAT CAT TCA were used to
amplify the full-length xFCP1 cDNA from pGEX4T2-xFCP1-wt. An
NheI-ClaI fragment of the PCR product (2,969 bp)
was inserted in frame with the N-terminal FLAG epitope coding sequence
in the pAdRSVFlag vector (a gift from François
Giudiccelli). Correct insertion was confirmed by sequencing. pAdRSVFlag
was derived from pAdRSVKrox20 by insertion of a FLAG epitope, a linker,
and a splice donor-acceptor sequence (16).
Expression of recombinant proteins, electrophoresis, and Western
blotting.
The pGEX4T2 expression plasmids were transformed in
Escherichia coli BL21-DE3 cells, and fusion proteins were
expressed by inducing an exponentially grown culture for 3 h at
37°C with 0.1 mM IPTG
(isopropyl-
-D-thiogalactopyranoside). Cells
were harvested, resuspended in phosphate-buffered saline, and
sonicated. The resulting lysates were bound to glutathione-Sepharose 4B
columns, and fusion proteins were purified according to the
manufacturer's instructions (Amersham Pharmacia Biotech).
Samples in Laemmli buffer were heated for 5 min at 95°C before being
loaded onto 5% polyacrylamide gels. Western blotting was carried out
with the following primary antibodies. Anti-Rpb1 recognizes a conserved
epitope on Rpb1 outside the CTD and was kindly provided by
E. K. Bautz (19). Anti-human FCP1 (anti-hFCP1) was
kindly provided by J. Greenblatt (1). Anti-glutathione S-transferase (anti-GST) and anti-FLAG (M2) were
purchased from Sigma. Anti-active MAPK (Promega) recognized the
phosphorylated Xp42. Reactive bands were visualized using horseradish
peroxidase-conjugated secondary antibodies (Promega) and
chemiluminescence (Pierce).
Nucleotide sequence accession number.
The xFCP1 sequence
data are available in GenBank under accession number AF348120.
 |
RESULTS |
CTD phosphatase activity in extracts from X.
laevis cells and eggs.
In X. laevis, fertilization is rapidly followed by a massive
dephosphorylation of the RNAP II CTD (4, 25). To
understand the basis of this phenomenon, the CTD phosphatase activity
was investigated in interphasic egg extracts. Phosphatase activity was
detected using 32P-labeled mammalian RNAP IIO and
by taking advantage of the slower electrophoretic mobility of the Rpb1
subunit when hyperphosphorylated on its CTD (subunit IIo). Upon
incubation in the frog egg extracts, the IIo subunit was gradually
replaced by the hypophosphorylated IIa subunit (Fig.
1A). Similarly, a low-salt extract from
A6 frog kidney cells dephosphorylated the CTD of mammalian RNAP II. The 32P end labeling did not significantly diminish
during the incubations, indicating that the phosphatase activity did
not remove the phosphate on the casein kinase II site that had been
used to label the Rpb1 subunit. CTD phosphatase activity was processive
in that the IIo subunit was transformed into the IIa subunit without
observable intermediates. Furthermore, CTD phosphatase extracted in a
low-salt buffer was insensitive to the usual phosphatase inhibitors,
i.e., okadaic acid and microcystin. Activity was totally
inhibited in the presence of moderate concentrations of
K+ ions (Fig. 1B). These features matched those
described for FCP1, the TFIIF-dependent CTD phosphatase that had been
characterized in human and yeast cells (1, 8, 14).
Thus, the CTD phosphatase activity detected in Xenopus cell
extracts might be due to a frog orthologue of FCP1.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
CTD phosphatase activity in Xenopus. (A)
Interphasic egg extracts or low-salt extracts from
Xenopus A6 cells were incubated with labeled RNAP IIO
for the amount of time indicated. (B) Extracts were incubated for 15 min with labeled RNAP IIO in the absence (control) or presence of 10 nM
okadaic acid (OA), 5 nM microcystin (mic), or 120 mM KCl (K+). The
labeled IIO form was incubated in pure buffer (-).
Dephosphorylation of the CTD was visualized by SDS-PAGE followed by
autoradiography. The positions of subunits IIa and IIo are indicated in
both panels.
|
|
Xenopus orthologue of the CTD phosphatase FCP1.
To clone the FCP1 frog orthologue, RNAs were isolated from A6 cells and
primers were designed by taking advantage of a Xenopus ovary
cDNA (GenBank accession number AJ132385) which had been reported to
potentially code for a protein of 868 amino acids (aa), sharing
homology with the hFCP1 sequence. A partial cDNA was subsequently
amplified by reverse transcription-PCR and sequenced (GenBank accession
number AF348120). It contains an open reading frame coding for a
protein of 980 aa. The new cDNA was highly similar to the original
ovary cDNA but differed by several point mutations, and more
significantly, it coded for a protein with a 112-aa-long extension at
its N terminus. The new amino acid sequence was more closely related to
the hFCP1 sequence (961 aa), especially on its N-terminal extension
(Fig. 2). Two highly conserved blocks of
homology were separated by a stretch of about 200 aa with weaker
similarities. These two blocks shared weak but still significant
homologies with the yeast FCP1 sequence. On the basis of these
homologies, the Xenopus protein was designated xFCP1 (for
Xenopus FCP1 orthologue).

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 2.
Alignment of FCP1 protein sequences. The human (Hs),
Xenopus (Xl), and yeast (Sc) FCP1 sequences were deduced
from their cDNA sequences (GenBank numbers AF154115, AF348120, and
NC_001145). The homologies are in gray shaded boxes. The dark boxes
enclose residues conserved in all three species. , crucial aspartate
residue.
|
|
To test the activity of the putative xFCP1 protein, its cDNA was cloned
adjacent to GST, and the fusion protein was expressed in bacteria. The
resulting GST-xFCP1 protein efficiently dephosphorylated RNAP IIO,
whereas GST alone did not (Fig. 3A).
Dephosphorylation of RNAP IIO by GST-xFCP1 was insensitive to okadaic
acid and microcystin but inhibited by mild concentrations of KCl (Fig.
3B). Kobor et al. have shown that the CTD phosphatase activity of the
yeast FCP1 is knocked out by replacement of aspartate by either
glutamate or asparagine in the LVVDLDQTII
peptide motif (18). Both the hFCP1 and xFCP1 protein
sequences contained the closely related motif
LMVDLDQTLI. Replacement of either
aspartate (D181 or D183) by glutamate or asparagine in the xFCP1
sequence suppressed the CTD phosphatase activity of the mutant
recombinant GST fusion proteins, although the same amount of the
proteins was used, as checked by anti-GST Western blot analysis (Fig.
3C). This finding highlights the similarity between the vertebrate and
yeast FCP1 proteins.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
X. laevis FCP1 exhibits
CTD phosphatase activity. (A) Labeled RNAP IIO was incubated for 10 min
with GST or increasing amounts of GST-xFCP1. (B) The experiment was
carried out in the absence (control) or presence of 10 nM okadaic acid
(OA), 5 nM microcystin (mic), or 120 mM KCl (K+). (C) Purified
wild-type or mutant GST-xFCP1 fusion proteins were incubated for 10 min
with labeled RNAP IIO. The amounts of the fusion proteins were checked
by Western blot analysis with a GST-specific antibody.
Dephosphorylation was visualized by SDS-PAGE and autoradiography.
Unreacted RNAP IIO was loaded as a control (-) in each experiment. The
positions of the subunits IIa and IIo are indicated in each panel.
|
|
CTD phosphatase activity in Xenopus extracts is
attributable to xFCP1.
An immunochemical analysis was employed to
establish whether or not the CTD phosphatase activity detected in
Xenopus extracts corresponded to xFCP1. An antiserum raised
against hFCP1 reacted with an
150-kDa polypeptide in human cell
extracts (1, 14). The same antiserum reacted with a
polypeptide of similar size in A6 cell extracts (Fig.
4A). The cDNA sequence is expected to encode a 110-kDa polypeptide. To make sure that the coding sequence was
complete, a FLAG epitope was fused to the N terminus of xFCP1 within a
eukaryotic expression vector. The resulting FLAG protein expressed in
transfected A6 cells comigrated with the protein detected by the
anti-FCP1 antiserum. The anti-hFCP1 reacted with the GST-xFCP1 fusion
protein with an apparent molecular mass close to 180 kDa, in agreement
with the addition of the GST moiety. Taken together, these experiments
strongly suggest that the cloned xFCP1 cDNA encodes a full-length
protein. In agreement with studies in both the yeast and mammalian
systems, these results indicate that the xFCP1 protein migration is
slower than expected from its theoretical molecular mass. As the
anti-hFCP1 cross-reacted with the xFCP1 protein, it was used to
immunodeplete A6 cell extract and egg extract (Fig. 4B). A
mock-depleted extract largely retained CTD phosphatase activity
as well as the xFCP1 protein, whereas the anti-hFCP1-depleted extract
did not. These results indicate that xFCP1 accounts for the major CTD
phosphatase activity in Xenopus extracts.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Xenopus CTD phosphatase activity is
attributable to xFCP1. (A) Low-salt A6 cell extract or purified
GST-xFCP1wt fusion protein was analyzed by SDS-PAGE and Western
blotting with anti-hFCP1 ( -hFCP1). Total lysates from control A6
cells or cells transfected with 5 µg of the plasmid encoding
FLAG-xFCP1 were analyzed with anti-FLAG ( -FLAG). The positions of
recombinant GST-xFCP1, endogenous xFCP1, and transfected FLAG-xFCP1 are
indicated. (B) Labeled RNAP IIO was incubated for 15 min with crude egg
or low-salt A6 cell extracts (control) which had been either mock or
xFCP1 ( -FCP1) depleted. CTD dephosphorylation was monitored as
indicated above. Nonincubated labeled RNAP IIO was loaded as a control
(-). The positions of the subunits IIa and IIo are indicated. The
presence of xFCP1 was checked by Western blotting.
|
|
RNAP II dephosphorylation requires xFCP1.
RNAP II
phosphorylation undergoes major changes during the first hours of
development (Fig. 5A). Fertilization
triggers a rapid and massive dephosphorylation of the CTD. Xp42 MAPK
deactivation has been proposed to be involved in this process
(4). To evaluate the contribution of xFCP1, advantage was
taken of the well-described preparation of Xenopus egg
extracts capable of supporting elaborate cellular functions
(24). The fertilization of metaphase II-arrested eggs can
be mimicked by addition of calcium to a meiotic CSF-arrested egg
extract. Interestingly, the dephosphorylation of RNAP IIO following
calcium activation was paralleled by a deactivation of Xp42 MAPK (Fig.
5B, lower part). Dephosphorylation of the CTD was complete after 60 min
(Fig. 5B, upper part), consistent with the pattern of CTD
phosphorylation in parthenogenetically activated or fertilized eggs. As
transcription resumes only at the midblastula transition, occurring 6 to 8 h after fertilization, the CTD dephosphorylation process takes place in the absence of transcription.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
CTD phosphorylation state after fertilization in
Xenopus. (A) CTD dephosphorylation after fertilization
in Xenopus embryos. Batches of 10 unfertilized eggs or
embryos were sampled; lysed at 0 (unfertilized eggs), 1, 2, or 3 h
postfertilization (hpf); and analyzed by SDS-PAGE along with a
whole-cell lysate from A6 cells. The phosphorylation state of the
largest RNAP II subunit was analyzed by Western blotting using an
anti-Rpb1 antibody. The positions of the subunits IIa and IIo are
indicated. (B) CTD dephosphorylation after in vitro activation of a
meiotic extract. Activation was performed at 22°C by adding
Ca2+ to the CSF-arrested meiotic extract for the indicated
time. The phosphorylation state of the CTD and the level of active MAPK
were analyzed by Western blotting with anti-Rpb1 and anti-active-MAPK
(MAPK-P) antibodies, respectively. The positions of the subunits IIa
and IIo are indicated. The presence of xFCP1 was checked by Western
blot analysis.
|
|
The consequence of xFCP1 depletion on the time course of CTD
dephosphorylation was investigated (Fig.
6A). xFCP1 protein was removed by
immunodepletion from a meiotic cell extract (Fig. 6B). Such
immunodepletion resulted in a significant Rpb1 hyperphosphorylation during incubation with the antibody-coated beads at 4°C. As the FCP1-immunodepleted extract was activated with
Ca2+, Rpb1 was slowly dephosphorylated and
returned only after 1 h to the RNAP IIO and IIA distribution found
in the initial nonactivated extract. In contrast, Rpb1 was rapidly
dephosphorylated in the mock-depleted activated extract as it was in
the untreated activated extract (compare Fig. 5B and 6B). These results
indicated that xFCP1 mediates the dephosphorylation of RNAP II upon
activation of Xenopus eggs. Note that the immunodepletion
did not affect deactivation of Xp42 MAPK following the addition of
calcium (Fig. 6B, lower part).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 6.
CTD dephosphorylation upon activation of a meiotic
extract requires xFCP1. (A) Experimental scheme. The CSF-arrested
extract was immunodepleted for 30 min at 4°C before activation by
Ca2+ at 22°C for the indicated time. Samples were taken
at the various time points as indicated (arrows) and analyzed by
Western blotting with the appropriate antibodies. (B) CTD
phosphorylation, active MAPK (MAPK-P), and FCP1 were analyzed in
untreated (U), mock-depleted (mock), and anti-FCP1-depleted ( -FCP1)
extracts. The positions of the subunits IIa and IIo are indicated.
|
|
Rapid CTD phosphate turnover in egg extracts.
To test whether
an increase in FCP1 activity would account for CTD dephosphorylation,
the CTD phosphatase activity was monitored during the course of
activation. However, a strong CTD kinase activity and the presence of
ATP in the egg extracts interfered with the assay. Hence, in order to
directly assay CTD phosphate turnover, RNAP IIO uniformly labeled on
the CTD repeats was added to meiotic egg extract. The phosphate label
was lost rapidly, within minutes, although the global IIo/IIa ratio
revealed by Western blotting did not change (Fig.
7A). This result indicates a rapid
phosphate turnover on the CTD. Indeed, the phosphorylation pattern of
RNAP II results from the balance between CTD kinase and phosphatase
activities. The egg extracts contain high levels of nonradioactive ATP
that may be used to rephosphorylate the CTD. Xp42 kinase, the major CTD
kinase in Xenopus egg extracts (4), is
deactivated upon egg activation (Fig. 5B). When RNAP IIO labeled on the
CTD repeats was added to activated egg extract, the phosphate label was
lost as rapidly as in the meiotic extract, indicating that CTD
phosphatase activity does not change upon egg activation (Fig. 7B).
Thus, Xp42 kinase activity alone might determine the level of CTD
phosphorylation.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 7.
Rapid CTD phosphate turnover in CSF-arrested and
interphasic egg extracts. (A) 32P-labeled (on the CTD
repeats) RNAP IIO was added to CSF-arrested egg extract. Samples were
analyzed after increasing incubation times by autoradiography and
Western blotting. The positions of the subunits IIa and IIo are
indicated. (B) 32P-labeled RNAP IIO was added to an egg
extract that was either unactivated ( ) or activated ( ) by
Ca2+ at 22°C for 60 min. The percentage of
radioactivity associated with subunit IIo (arbitrary units) is plotted
as a function of time.
|
|
 |
DISCUSSION |
These studies report the molecular cloning of the cDNA encoding
the full-length Xenopus orthologue of the human and yeast FCP1 CTD phosphatases and examine the role of xFCP1 in early
development. Fertilization triggers a rapid and massive CTD
dephosphorylation. This pattern of dephosphorylation, which can be
reproduced upon calcium activation of CSF-arrested egg extracts, is
dependent on the activity of xFCP1. Finally, the rapid turnover of CTD
phosphates that occurs during early development appears to be
independent of transcription.
xFCP1, a nonconventional evolutionarily conserved protein
phosphatase.
FCP1-related sequences are found in
Schizosaccharomyces pombe, Aspergillus
nidulans, Arabidopsis thaliana, Caenorhabditis elegans, and Drosophila melanogaster genomes. All
of these putative FCP1 orthologues share the same two blocks of
homology. The N-terminal domain, i.e., the FCP1 domain, contains a
motif related to the consensus sequence


DXDX(T/V)
(where
designates
hydrophobic amino acids) found in a family of phosphotransferases and
phosphohydrolases using small phosphocompounds as substrates.
Mutagenesis of the aspartate residues in this motif abolishes the CTD
phosphatase activity of yeast FCP1 (18). We now
show that replacement of either of the corresponding aspartate residues
by glutamate or asparagine in vertebrate FCP1 has the same effect.
Homology between members of the FCP1 family allows the definition of
two functional domains in the protein. The N terminus contains the
catalytic site with the double-aspartate motif, whereas the C terminus
contains a putative TFIIF-interacting domain identified by biochemical or genetic studies of human and yeast cells (1, 9).
A divergent zone is observed between the two domains. Despite the
significant differences between the human and frog FCP1 sequences,
mammalian RNAP IIO is an appropriate substrate for the frog enzyme.
CTD phosphorylation
a highly dynamic process even without
transcription.
Previous studies have established that
phosphorylation of the CTD is closely linked to the transcription cycle
(12). Indeed, different kinases which utilize RNAP II as a
substrate are present in the transcriptional apparatus. As a subunit of
TFIIH, CDK7 or its yeast orthologue, KIN28, may phosphorylate
the CTD during initiation, whereas CDK9, a subunit of P-TEFb, may
act during the elongation process (21, 26, 28). Inhibition
of KIN28 in S. cerevisiae (30) or
inhibition of CDK9 in somatic vertebrate cells (7, 15)
leads to a rapid dephosphorylation of the CTD. Conversely, inhibition
of FCP1 in S. cerevisiae results in CTD hyperphosphorylation (18).
The CTD is phosphorylated when stage VI Xenopus oocytes
enter meiosis, whereas egg activation or fertilization is followed by a
rapid dephosphorylation of the CTD (4). Importantly, no transcription is detected at these stages. A minor CTD phosphorylation involving MAPK occurs independent of transcription in mammalian (6) and Xenopus cells (25). In the
Xenopus oocyte and activated egg system, CTD phosphorylation
correlates with the activity of Xp42 MAPK. When MAPK activation is
prevented, meiotic CTD phosphorylation does not occur (4).
As Xp42 is the major CTD kinase found in metaphase II egg extracts, it
is likely to be a major player in CTD phosphorylation in this system in
which no transcription is detected. In this report, xFCP1 is shown to
account for the CTD phosphatase activity present in an egg extract.
Removal of FCP1 from a meiotic extract leads to an enhanced CTD
phosphorylation. Furthermore, CTD dephosphorylation is strongly
attenuated in activated extracts depleted of FCP1. These findings
indicate that phosphorylation of RNAP II in this system is tightly
regulated and that Xp42 and FCP1 are the major players in this
regulation. Since FCP1 CTD phosphatase activity does not change upon
egg activation, Xp42 MAPK activity alone might determine the level of
CTD phosphorylation. Since transcription does not occur in metaphase
oocytes and early embryos, the MAPK- and FCP1-regulated
phosphorylation of RNAP II proceeds independent of transcription (Fig.
8A).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 8.
A model of two distinct CTD phosphorylation cycles. The
FCP1 CTD phosphatase may counteract distinct CTD kinases in early
embryos (A) or somatic cells (B).
|
|
Dephosphorylation of RNAP II by FCP1 is uncoupled from
transcription.
FCP1 has been shown to ensure the recycling of RNAP
II (10). The CTD is phosphorylated upon entry into
elongation and must be dephosphorylated to allow the formation of
subsequent preinitiation complexes (12). CTD
dephosphorylation after fertilization might thus contribute to the
preparation of the transcriptional machinery for zygotic genome
activation. It remains a challenge to establish at which point in the
transcription cycle CTD dephosphorylation takes place. In this report,
we show that xFCP1 efficiently dephosphorylates RNAP II during meiosis
and during the first cell cycles that follow fertilization in
X. laevis. As no transcription occurs at these stages, our data indicate that FCP1 dephosphorylates free RNAP II in
vivo. In somatic cells, FCP1 is not tightly bound to chromatin because
it is fully extracted in a low-salt buffer (14; this report). Furthermore, the CTD in elongation complexes is a poor substrate for FCP1 (22, 23). In transcribing cells, CTD
rephosphorylation would occur on DNA-bound initiation complexes upon
entry into elongation of transcription (Fig. 8B). A phosphorylated CTD
might be required until pre-mRNA synthesis is completed, as it
contributes to enhanced cleavage and polyadenylation of the transcript
(2, 17). Although a change in the sensitivity of RNAP IIO
in an elongation complex could indeed initiate the process of
termination, it is tempting to speculate that CTD dephosphorylation
could occur on free RNAP II released from DNA in the nucleoplasm
following termination.
This work was supported by grants from the Association pour la
Recherche sur le Cancer (grant no. ARC 6250 to O.B.) and the Ligue Nationale Contre le Cancer (to O.B.).
We are much indebted to François Giudicelli, Jack Greenblatt,
Olivier Jeanjean, Michael Kobor, and Daniela Marazziti for plasmids and
reagents; to Olivier Hyrien and colleagues for Xenopus handling; and to Fréderic Gabriel and all members of the
laboratory for help and discussions.
| 1.
|
Archambault, J.,
G. Pan,
G. K. Dahmus,
M. Cartier,
N. F. Marshall,
S. Zhang,
M. E. Dahmus, and J. Greenblatt.
1998.
FCP1, the RAP74-interacting subunit of a human protein phosphatase that dephosphorylates the carboxyl-terminal domain of RNA polymerase IIO.
J. Biol. Chem.
273:27593-27601[Abstract/Free Full Text].
|
| 2.
|
Barillà, D.,
B. A. Lee, and N. J. Proudfoot.
2001.
Cleavage/polyadenylation factor IA associates with the carboxyl-terminal domain of RNA polymerase II in Saccharomyces cerevisiae.
Proc. Natl. Acad. Sci. USA
98:445-450[Abstract/Free Full Text].
|
| 3.
|
Bellier, S.,
S. Chastant,
P. Adenot,
M. Vincent,
J.-P. Renard, and O. Bensaude.
1997.
Nuclear translocation and carboxyl-terminal domain phosphorylation of RNA polymerase II delineate the two phases of zygotic gene activation in mammalian embryos.
EMBO J.
16:6250-6262[CrossRef][Medline].
|
| 4.
|
Bellier, S.,
M.-F. Dubois,
E. Nishida,
G. Almouzni, and O. Bensaude.
1997.
Phosphorylation of the RNA polymerase II largest subunit during Xenopus laevis oocyte maturation.
Mol. Cell. Biol.
17:1434-1440[Abstract].
|
| 5.
|
Bensaude, O.,
F. Bonnet,
C. Cassé,
M.-F. Dubois,
V.-T. Nguyen, and B. Palancade.
1999.
Regulated phosphorylation of the RNA polymerase II C-terminal domain (CTD).
Biochem. Cell Biol.
77:1-7[CrossRef][Medline].
|
| 6.
|
Bonnet, F.,
M. Vigneron,
O. Bensaude, and M.-F. Dubois.
1999.
Transcription-independent phosphorylation of the RNA polymerase II carboxy-terminal domain (CTD) requiring ERK kinase activity.
Nucleic Acids Res.
27:4399-4404[Abstract/Free Full Text].
|
| 7.
|
Cassé, C.,
F. Giannoni,
V. T. Nguyen,
M.-F. Dubois, and O. Bensaude.
1999.
The transcriptional inhibitors, actinomycin D and -amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II C-terminal domain.
J. Biol. Chem.
274:16097-16106[Abstract/Free Full Text].
|
| 8.
|
Chambers, R. S., and M. E. Dahmus.
1994.
Purification and characterization of a phosphatase from HeLa cells that dephosphorylates the C-terminal domain of RNA polymerase II.
J. Biol. Chem.
269:26243-26248[Abstract/Free Full Text].
|
| 9.
|
Chambers, R. S.,
B. Q. Wang,
Z. F. Burton, and M. E. Dahmus.
1995.
The activity of COOH-terminal domain phosphatase is regulated by a docking site on RNA polymerase II and by the general transcription factors IIF and IIB.
J. Biol. Chem.
270:14962-14969[Abstract/Free Full Text].
|
| 10.
|
Cho, H.,
T. K. Kim,
H. Mancebo,
W. S. Lane,
O. Flores, and D. Reinberg.
1999.
A protein phosphatase functions to recycle RNA polymerase II.
Genes Dev.
13:1540-1552[Abstract/Free Full Text].
|
| 11.
|
Corden, J. L., and M. Patturajan.
1997.
A CTD function linking transcription to splicing.
Trends Biochem. Sci.
22:413-416[CrossRef][Medline].
|
| 12.
|
Dahmus, M. E.
1996.
Reversible phosphorylation of the C-terminal domain of RNA polymerase II.
J. Biol. Chem.
271:19009-19012[Free Full Text].
|
| 13.
|
Davidson, E. H.
1986.
Gene activity in early development, 3rd ed.
Academic Press, Inc., Orlando, Fla.
|
| 14.
|
Dubois, M. F.,
N. F. Marshall,
V. T. Nguyen,
G. K. Dahmus,
F. Bonnet,
M. E. Dahmus, and O. Bensaude.
1999.
Heat shock of HeLa cells inactivates a nuclear protein phosphatase specific for dephosphorylation of the C-terminal domain (CTD) of RNA polymerase II.
Nucleic Acids Res.
27:1338-1344[Abstract/Free Full Text].
|
| 15.
|
Dubois, M. F.,
V. T. Nguyen,
S. Bellier, and O. Bensaude.
1994.
Inhibitors of transcription such as 5,6-dichloro-1- -D-ribofuranosyl benzimidazole (DRB) and isoquinoline sulfonamide derivatives (H-8 and H-7*) promote the dephosphorylation of the C-terminal domain (CTD) of RNA polymerase II largest subunit.
J. Biol. Chem.
269:13331-13336[Abstract/Free Full Text].
|
| 16.
|
Giudicelli, F.,
E. Taillebourg,
P. Charnay, and P. Gilardi-Hebenstreit.
2001.
Krox-20 patterns the hindbrain through both cell-autonomous and non cell-autonomous mechanisms.
Genes Dev.
15:567-580[Abstract/Free Full Text].
|
| 17.
|
Hirose, Y., and J. L. Manley.
1998.
RNA polymerase II is an essential mRNA polyadenylation factor.
Nature
395:93-96[CrossRef][Medline].
|
| 18.
|
Kobor, M. S.,
J. Archambault,
W. Lester,
F. C. Holstege,
O. Gileadi,
D. B. Jansma,
E. G. Jennings,
F. Kouyoumdjian,
A. R. Davidson,
R. A. Young, and J. Greenblatt.
1999.
An unusual eukaryotic protein phosphatase required for transcription by RNA polymerase II and CTD dephosphorylation in S. cerevisiae.
Mol. Cell
4:55-62[CrossRef][Medline].
|
| 19.
|
Kontermann, R. E.,
Z. Liu,
R. A. Schulze,
K. A. Sommer,
I. Queitsch,
S. Dubel,
S. M. Kipriyanov,
F. Breitling, and E. K. Bautz.
1995.
Characterization of the epitope recognized by a monoclonal antibody directed against the largest subunit of Drosophila RNA polymerase II.
Biol. Chem. Hoppe-Seyler.
376:473-481[Medline].
|
| 20.
|
Leclerc, V.,
S. Raisin, and P. Leopold.
2000.
Dominant-negative mutants reveal a role for the Cdk7 kinase at the mid-blastula transition in Drosophila embryos.
EMBO J.
19:1567-1575[CrossRef][Medline].
|
| 21.
|
Lee, T. I., and R. A. Young.
2000.
Transcription of eukaryotic protein-coding genes.
Annu. Rev. Genet.
34:77-137[CrossRef][Medline].
|
| 22.
|
Lehman, A. L., and M. E. Dahmus.
2000.
The sensitivity of RNA polymerase II in elongation complexes to C-terminal domain phosphatase.
J. Biol. Chem.
275:14923-14932[Abstract/Free Full Text].
|
| 23.
|
Marshall, N. F., and M. E. Dahmus.
2000.
C-terminal domain phosphatase sensitivity of RNA polymerase II in early elongation complexes on the HIV-1 and adenovirus 2 major late templates.
J. Biol. Chem.
275:32430-32437[Abstract/Free Full Text].
|
| 24.
|
Murray, A. W.
1991.
Cell cycle extracts.
Methods Cell Biol.
36:581-605[Medline].
|
| 25.
| Palancade, B., S. Bellier, G. Almouzni, and O. Bensaude. Incomplete RNA polymerase II phosphorylation in Xenopus
laevis early embryos. J. Cell Sci., in press.
|
| 26.
|
Price, D. H.
2000.
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.
Mol. Cell. Biol.
20:2629-2634[Free Full Text].
|
| 27.
|
Seydoux, G., and M. A. Dunn.
1997.
Transcriptionally-repressed germ cells lack a subpopulation of phosphorylated RNA polymerase II in early embryos of C. elegans and D. melanogaster.
Development
124:2191-2201[Abstract].
|
| 28.
|
Svejstrup, J. Q.,
P. Vichi, and J.-M. Egly.
1996.
The multiple roles of transcription/repair factor TFIIH.
Trends Biochem. Sci.
21:346-350[CrossRef][Medline].
|
| 29.
|
Swedlow, J. R.
1999.
Chromosome assembly in vitro using Xenopus egg extracts, p. 167-182.
In
W. A. Bickmore (ed.), Chromosome structural analysis: a practical approach. Oxford University Press, Oxford, United Kingdom.
|
| 30.
|
Valay, J.-G.,
M. Simon,
M.-F. Dubois,
O. Bensaude,
C. Facca, and G. Faye.
1995.
The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD.
J. Mol. Biol.
249:535-544[CrossRef][Medline].
|